Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

10. November 2022 09:00 ET | Quelle: Cue Biopharma, Inc.

Cue Biopharma Presents New Positive Data from Ongoing Phase 1 Trial of CUE-101 in Combination with KEYTRUDA(R) for Recurrent/Metastatic HPV+ Head and Neck Cancer at the Society for Immunotherapy of Cancer’s (SITC) 37th Annual Meeting

Overall response rate (ORR) of 40% and a clinical benefit rate (CBR) of 70% observed to date in first line (1L) recurrent/metastatic HNSCC patients treated with CUE-101 at the recommended Phase 2 dose...
09. November 2022 08:00 ET | Quelle: Cue Biopharma, Inc.

Cue Biopharma to Present at Two Upcoming Investor Healthcare Conferences in November

BOSTON, Nov. 09, 2022 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of injectable biologics to selectively engage and...
07. November 2022 08:00 ET | Quelle: Cue Biopharma, Inc.

Cue Biopharma to Host Business Update Call and Webcast

BOSTON, Nov. 07, 2022 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of injectable biologics to selectively engage and...
05. Oktober 2022 08:00 ET | Quelle: Cue Biopharma, Inc.

Cue Biopharma Announces Upcoming Scientific Presentations at the Society for Immunotherapy of Cancer’s (SITC) 37th Annual Meeting

BOSTON, Oct. 05, 2022 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of injectable biologics to selectively engage and...
04. Oktober 2022 08:00 ET | Quelle: Cue Biopharma, Inc.

Cue Biopharma Granted FDA Fast Track Designation for CUE-101 for the Treatment of Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

BOSTON, Oct. 04, 2022 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of injectable biologics designed to selectively...
07. September 2022 08:00 ET | Quelle: Cue Biopharma, Inc.

Cue Biopharma to Present at Two September 2022 Scientific Conferences

BOSTON, Sept. 07, 2022 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of injectable biologics to selectively engage and...
22. August 2022 08:00 ET | Quelle: Cue Biopharma, Inc.

Cue Biopharma Doses First Patient in Phase 1 Study of CUE-102 for Wilms’ Tumor 1 (WT1) - expressing cancers

BOSTON, Aug. 22, 2022 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of injectable biologics to selectively engage and...
04. August 2022 16:30 ET | Quelle: Cue Biopharma, Inc.

Cue Biopharma Reports Second Quarter 2022 Financial Results

BOSTON, Aug. 04, 2022 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of injectable biologics to selectively engage and...
11. Juli 2022 08:00 ET | Quelle: Cue Biopharma, Inc.

Cue Biopharma to Present at the Guggenheim I&I Spotlight Series

BOSTON, July 11, 2022 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of injectable biologics to selectively engage and...
13. Juni 2022 08:00 ET | Quelle: Cue Biopharma, Inc.

Cue Biopharma to Present at the JMP Securities Life Sciences Conference

BOSTON, June 13, 2022 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of injectable biologics to selectively engage and...

Vorherige Seite

Nächste Seite